Myeloperoxidase (MPO, EC 1.11.1.7) is a heme-based peroxidase enzyme responsible for antimicrobial activity against a wide range of organisms. This enzyme is copiously expressed in stimulated neutrophil granulocytes, where it catalyzes the production of hypohalous acids, from hydrogen peroxide (H2O2) and halides (Cl-, Br-, I-). Hypochlorous acid (HOCl or in less extent HOBr and HOI) generated by MPO and also reactive oxygen species (ROS) are involved in the microbicidal activity of neutrophils, contributing to innate host defenses [1]. But increased level of MPO in neutrophils and in blood may be accompanied by the hyperproduction of hypochlorous acid and ROS, which leads to the development of halogenating stress in the organism. This can cause inflammation and subsequently leads to various pathologies, such as Alzheimer's disease, cardiovascular disease, diabetes, malignant tumors, etc. [2]. Therefore, the search for drugs that regulate the oxygen-activating function of neutrophils and the development of new approaches aimed at preventing the occurrence of halogenating stress in the body are very important at present.
Previously we studied influence of catechol derivatives on ROS generation by neutrophils stimulated to phagocytosis. It was shown that 4,6-di-tert-butyl-3-(((2-mercaptophenyl)imino)methyl) benzene-1,2-diol (S1), 4,6-di-tert-butyl-3-(((2-mercaptoethyl)imino)methyl)benzene-1,2-diol (S2), 4,6-di-tert-butyl-3-((2-phenylhydrazineylidene)methyl)benzene-1,2-diol (S3) and N'-(2,3-dihydroxybenzylidene) isonicotinohydrazide (S4) cells in micromolar concentrations effectively decrease ROS production of due to MPO inhibition, but not NADPH oxidase inhibition. No one of analyzed compounds has cytotoxic effect on neutrophils [3].
The purpose of our study was to find out the mechanism of MPO inhibition by catechol derivatives.
Neutrophils were allocated from blood of healthy people on the basis of a standard method. Cells were destroyed in three cycles of freezing and thawing. The resulting mixture was centrifuged. The supernatant containing free MPO was used for the analysis. The enzyme activity was determined by its ability to generate HOCl and ROS. The formation of ROS and HOCl was registered by chemiluminescent method at the temperature of 37°C in Earl's solution containing H2O2 and luminol. Measurements were conducted using biochemiluminometer BHL-1 (BSU, Belarus). The concentration of catechol derivatives in the analyzed probe was equal to 4 μM.
Kinetic curves of ROS and HOCl production in the system «MPO-H2O2-luminol» with analyzed compounds and without them in reversed Lineweaver-Burk plot were obtained. It was found that S1 inhibits the enzyme by uncompetitive way while S2, S3, S4 decrease enzyme activity by mixed inhibition.
Also computer modeling was used to estimate ability of the compounds under consideration to act as MPO ligands (substrates or inhibitors). Affinity of the compounds was assessed using Autodock 4.2 and AutoDockTools software. Human MPO three-dimensional structures were downloaded from www.pdb.org database (PDB ids: 4dl1, 4c1m and 1dnw). The calculations demonstrated that S3 and S1 have the highest affinity to MPO active site among compounds tested (Table 1).
| Ligand | Ki, M |
|---|---|
| S1 | $2.67 \cdot 10^{-7} - 4.26 \cdot 10^{-7}$ |
| S3 | $3.27 \cdot 10^{-7} - 6.05 \cdot 10^{-7}$ |
| S4 | $1.07 \cdot 10^{-6} - 2.68 \cdot 10^{-6}$ |
| S2 | $1.28 \cdot 10^{-6} - 2.90 \cdot 10^{-5}$ |
The values of the inhibition constants (Ki) obtained in mathematical modeling correlate with the previously obtained experimental data [3].
The data altogether indicate that the compounds might affect MPO activity via interaction with MPO at not only catalytic site, giving us promising starting point for further research of catechol derivatives as potential medicines for inhibiting myeloperoxidase and preventing halogenating stress in the organism.